1. Home
  2. EPOW vs LITS Comparison

EPOW vs LITS Comparison

Compare EPOW & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

EPOW

Sunrise New Energy Co. Ltd

HOLD

Current Price

$0.48

Market Cap

24.2M

ML Signal

HOLD

LITS

Lite Strategy Inc.

HOLD

Current Price

$0.93

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EPOW
LITS
Founded
2014
2000
Country
China
United States
Employees
N/A
4
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.2M
25.7M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
EPOW
LITS
Price
$0.48
$0.93
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
33.8K
135.2K
Earning Date
05-15-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.39
$0.69
52 Week High
$1.86
$3.03

Technical Indicators

Market Signals
Indicator
EPOW
LITS
Relative Strength Index (RSI) 32.30 44.55
Support Level $0.40 $0.79
Resistance Level $0.72 $0.99
Average True Range (ATR) 0.04 0.06
MACD -0.00 -0.01
Stochastic Oscillator 9.95 16.10

Price Performance

Historical Comparison
EPOW
LITS

About EPOW Sunrise New Energy Co. Ltd

E Power Inc, through its subsidiaries, is engaged in the manufacturing and sale of graphite anode material for lithium-ion batteries. It operates a plant in Guizhou Province, China, powered by electricity from renewable sources, which contributes to the plant's low production costs and reduced environmental impact in the production of graphite anode materials. Additionally, the Group also operates a knowledge-sharing platform business. Its reportable operating segments are: Graphite anode business, which generates the maximum revenue, and Knowledge sharing and enterprise business. Substantially all of the Group's revenue is derived in the People's Republic of China (the PRC).

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: